DE60202452C5 - Pyridazinonaldose reductase inhibitoren - Google Patents

Pyridazinonaldose reductase inhibitoren Download PDF

Info

Publication number
DE60202452C5
DE60202452C5 DE60202452T DE60202452T DE60202452C5 DE 60202452 C5 DE60202452 C5 DE 60202452C5 DE 60202452 T DE60202452 T DE 60202452T DE 60202452 T DE60202452 T DE 60202452T DE 60202452 C5 DE60202452 C5 DE 60202452C5
Authority
DE
Germany
Prior art keywords
pyridazin
alkyl
sulfonyl
het
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60202452T
Other languages
German (de)
English (en)
Other versions
DE60202452D1 (de
DE60202452T2 (de
Inventor
Lakshman Banavara MYLARI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of DE60202452D1 publication Critical patent/DE60202452D1/de
Application granted granted Critical
Publication of DE60202452T2 publication Critical patent/DE60202452T2/de
Publication of DE60202452C5 publication Critical patent/DE60202452C5/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60202452T 2001-03-30 2002-01-31 Pyridazinonaldose reductase inhibitoren Expired - Fee Related DE60202452C5 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28005101P 2001-03-30 2001-03-30
US280051P 2001-03-30
PCT/IB2002/000320 WO2002079198A1 (en) 2001-03-30 2002-01-31 Pyridazinone aldose reductase inhibitors

Publications (3)

Publication Number Publication Date
DE60202452D1 DE60202452D1 (de) 2005-02-03
DE60202452T2 DE60202452T2 (de) 2006-02-09
DE60202452C5 true DE60202452C5 (de) 2006-11-23

Family

ID=23071435

Family Applications (3)

Application Number Title Priority Date Filing Date
DE60202452T Expired - Fee Related DE60202452C5 (de) 2001-03-30 2002-01-31 Pyridazinonaldose reductase inhibitoren
DE60216823T Expired - Fee Related DE60216823T2 (de) 2001-03-30 2002-01-31 Zwischenprodukten für die Herstellung von Pyridazinon Aldose Reductase Inhibitoren.
DE60217930T Expired - Fee Related DE60217930T2 (de) 2001-03-30 2002-01-31 Pyridazinon Aldose Reductase Inhibitoren

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE60216823T Expired - Fee Related DE60216823T2 (de) 2001-03-30 2002-01-31 Zwischenprodukten für die Herstellung von Pyridazinon Aldose Reductase Inhibitoren.
DE60217930T Expired - Fee Related DE60217930T2 (de) 2001-03-30 2002-01-31 Pyridazinon Aldose Reductase Inhibitoren

Country Status (43)

Country Link
US (2) US6579879B2 (enExample)
EP (3) EP1491541B1 (enExample)
JP (1) JP2004528319A (enExample)
KR (1) KR100586138B1 (enExample)
CN (1) CN1215067C (enExample)
AP (1) AP2002002461A0 (enExample)
AR (1) AR035798A1 (enExample)
AT (3) ATE348100T1 (enExample)
AU (1) AU2002226634B2 (enExample)
BG (1) BG108179A (enExample)
BR (1) BR0208571A (enExample)
CA (1) CA2442476A1 (enExample)
CZ (1) CZ20032563A3 (enExample)
DE (3) DE60202452C5 (enExample)
DK (2) DK1373259T3 (enExample)
EA (1) EA006023B1 (enExample)
EC (1) ECSP034671A (enExample)
EE (1) EE200300470A (enExample)
ES (2) ES2231681T3 (enExample)
GE (1) GEP20053675B (enExample)
HR (1) HRP20030752A2 (enExample)
HU (1) HUP0303644A3 (enExample)
IL (1) IL156462A0 (enExample)
IS (3) IS2205B (enExample)
MA (1) MA27003A1 (enExample)
MX (1) MXPA03008850A (enExample)
MY (1) MY134304A (enExample)
NO (1) NO20034345L (enExample)
NZ (1) NZ528406A (enExample)
OA (1) OA12453A (enExample)
PA (1) PA8541801A1 (enExample)
PE (1) PE20030007A1 (enExample)
PL (1) PL365294A1 (enExample)
PT (2) PT1491540E (enExample)
SI (1) SI1373259T1 (enExample)
SK (1) SK11852003A3 (enExample)
TN (1) TNSN02037A1 (enExample)
TW (1) TWI245762B (enExample)
UA (1) UA73236C2 (enExample)
UY (1) UY27237A1 (enExample)
WO (1) WO2002079198A1 (enExample)
YU (1) YU71403A (enExample)
ZA (1) ZA200304671B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001876A (en) 1996-07-24 1999-12-14 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
ES2240657T3 (es) * 2001-02-28 2005-10-16 Pfizer Products Inc. Compuestos de sulfonilpiridazinona utiles como inhibidores de aldosa reductasa.
ATE348100T1 (de) * 2001-03-30 2007-01-15 Pfizer Prod Inc Zwischenprodukten für die herstellung von pyridazinon aldose reductase inhibitoren.
AU761191B2 (en) * 2001-05-24 2003-05-29 Pfizer Products Inc. Therapies for tissue damage resulting from ischemia
CN1269814C (zh) 2002-01-09 2006-08-16 辉瑞产品公司 哒嗪酮抗糖尿病药的制备方法和中间体
US20040092522A1 (en) * 2002-08-15 2004-05-13 Field Mark John Synergistic combinations
US7419981B2 (en) * 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US6872833B2 (en) * 2003-04-14 2005-03-29 Hoffmann-La Roche Inc. Adenosine receptor ligands
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
CA2568640C (en) 2004-06-04 2011-08-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
US20060035251A1 (en) * 2004-06-30 2006-02-16 Whitehead Institute For Biomedical Research Novel methods for high-throughput genome-wide location analysis
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
BRPI0706523A2 (pt) * 2006-01-13 2011-01-04 Wyeth Corp composto de fórmula i; composição farmacêutica; método de tratamento de distúrbios que estão relacionados com ou são afetados pela inibição da recaptação de norepinefrina, o receptor de 5-ht6 ou o receptor de 5-ht2a; método de tratamento de um distúrbio de aprendizado, de um distúrbio cognitivo, de um distúrbio de memória, de um distúrbio de personalidade, de um distúrbio comportamental, de um distúrbio de movimento, de um distúrbio neurodegenerativo, de abstinência de droga, de distúrbio de sono, de um distúrbio alimentar, de uma toxicidade de droga aguda, de um distúrbio cardiovascular, de uma disfunção sexual, de um distúrbio gastrintestinal, de um distúrbio genitourinário, de um distúrbio de dor, de um distúrbio nervoso ou de um distúrbio de sintoma vasomotor; método de tratamento de doença de alzheimer, de um distúrbio de deficiência da atenção, de esquizofrenia, de doença de parkinson, de discinésia tardia, de ataxia, de bradicinésia, de discinésias paroxìsmicas, de sìndrome da perna irrequieta, de tremor, de tremor essencial, de epilepsia, de apoplexia ou de trauma na cabeça; método de tratamento de doença arterial coronariana, de enfarte do miocárdio, de ataque isquêmico transitório, de angina, de fibrilação atrial, de agregação plaquetária, de risco de formação de coágulo sanguìneo, de sìndrome do intestino irritável, de constipação crÈnica, de doença do refluxo gastrintestinal, de dispepsia, de incontinência urinária por estresse ou de incontinência urinária de urgência; método de tratamento de depressão, de distúrbio compulsivo obsessivo, de tendência ao suicìdio, de distúrbio de ansiedade, de distúrbio bipolar, de distúrbio de pánico, de abstinência de nicotina, de abstinência de álcool, de abstinência de cocaìna, de abstinência de heroìna, de abstinência de anfetamina, de abstinência de drogas narcóticas, de insÈnia, de apnéia do sono, de narcolepsia, de distúrbio afetivo sanzonal, de sìndrome da perna irrequieta, de distúrbio de sono de turno de trabalho, de sìndrome da fase do sono retardada, de anorexia nervosa, de bulimia nervosa, de sìndrome do comer noturno, de superalimentação compulsiva, de sìndrome da fadiga crÈnica, de fibromialgia, de neuropatia de dor, de dor antinociceptiva, de sìndrome da dor crÈnica, de neuropatia diabética, de fogacho ou de suor noturno; e uso de um composto
CL2007001873A1 (es) * 2006-06-27 2008-01-04 Takeda Pharmaceutical Acido((3s))-6-((¨2,6-dimetil-4-(3-(metilsulfonil)-propoxi)bifenil-3-il)metoxi-2,3-dihidro-1-benzofuran-3-il)acetico o una sal del mismo
JP5498168B2 (ja) 2006-12-01 2014-05-21 ブリストル−マイヤーズ スクイブ カンパニー アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体
WO2008116107A2 (en) * 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
EP2509596B1 (en) 2009-12-08 2019-08-28 Case Western Reserve University Gamma aminoacids for treating ocular disorders
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
CA2848877A1 (en) * 2011-09-15 2013-03-21 Taipei Medical University Use of indolyl and indolinvl hvdroxamates for treating heart failure or neuronal injury
US9339542B2 (en) * 2013-04-16 2016-05-17 John L Couvaras Hypertension reducing composition
SG11201507496UA (en) 2013-04-17 2015-11-27 Pfizer N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
CN103739547B (zh) * 2014-01-03 2015-09-02 沈阳药科大学 2-[6-甲氧基-3-(2,3-二氯苯基)甲基-4-氧代-1,4-二氢-1(4h)-喹啉基]乙酸的合成方法
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
JP2018511616A (ja) * 2015-04-14 2018-04-26 ケース ウエスタン リザーブ ユニバーシティ 短鎖デヒドロゲナーゼ活性を調節する組成物および方法
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
IL283809B2 (en) 2016-06-21 2024-01-01 Univ Columbia Compounds for use in a method of treating neuropathy, retinopathy, nephropathy, or cardiomyopathy
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
US10344002B2 (en) 2016-09-26 2019-07-09 Nusirt Sciences, Inc. Compositions and methods for treating metabolic disorders
EP3548035A4 (en) 2016-11-30 2020-07-22 Case Western Reserve University COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES
AU2018215678A1 (en) 2017-02-06 2019-08-22 Board Of Regents Of The University Of Texas System Compositions and methods of modulating short-chain dehydrogenase activity
IL272246B2 (en) 2017-07-28 2026-01-01 Applied Therapeutics Inc History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications
IL321451A (en) 2018-11-21 2025-08-01 Univ Case Western Reserve Compositions and methods of modulating short-chain dehydrogenase activity
US11248001B2 (en) 2019-01-18 2022-02-15 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
AU2020254610A1 (en) 2019-04-01 2021-11-18 Applied Therapeutics Inc. Inhibitors of aldose reductase
CN113966396A (zh) 2019-05-07 2022-01-21 迈阿密大学 遗传性神经病和相关障碍的治疗和检测
US11274082B2 (en) 2019-05-31 2022-03-15 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2020243423A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
MX2022010258A (es) 2020-02-21 2023-01-24 Univ Case Western Reserve Composiciones y métodos para tratar la lesión renal.
WO2022120353A1 (en) * 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE47592B1 (en) 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4996204A (en) 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
FR2647676A1 (fr) 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
EP0516860A4 (en) * 1990-11-30 1993-12-01 Tsumura & Co. Chromone derivative and aldose reductase inhibitor containing the same as active ingredient
CZ387092A3 (en) 1991-03-28 1994-02-16 Pfizer Pyridazinoacetic acids, their derivatives, process of their preparation and use
US5834466A (en) 1994-12-22 1998-11-10 The Regents Of The University Of California Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
TR200000764T2 (tr) * 1997-09-24 2001-03-21 Orion Corporation Fosfolamban inhibitörleri olarak, 1-okza, aza ve tiyanaftalin-2-on'ların biseterleri.
FR2822827B1 (fr) * 2001-03-28 2003-05-16 Sanofi Synthelabo Nouveaux derives de n-(arylsulfonyl) beta-aminoacides comportant un groupe aminomethyle substitue, leur procede de preparation et les compositions pharmaceutiques en contenant
ATE348100T1 (de) * 2001-03-30 2007-01-15 Pfizer Prod Inc Zwischenprodukten für die herstellung von pyridazinon aldose reductase inhibitoren.
AU2002236131B2 (en) * 2001-04-30 2005-04-14 Pfizer Products Inc. Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors
CN1269814C (zh) * 2002-01-09 2006-08-16 辉瑞产品公司 哒嗪酮抗糖尿病药的制备方法和中间体

Also Published As

Publication number Publication date
HUP0303644A2 (hu) 2004-03-01
ZA200304671B (en) 2004-06-25
TWI245762B (en) 2005-12-21
EP1491541A1 (en) 2004-12-29
KR100586138B1 (ko) 2006-06-07
MY134304A (en) 2007-12-31
DK1373259T3 (da) 2005-03-29
PT1491540E (pt) 2007-01-31
CZ20032563A3 (cs) 2004-05-12
YU71403A (sh) 2006-05-25
NO20034345D0 (no) 2003-09-29
DE60217930T2 (de) 2007-10-18
HK1061678A1 (en) 2004-09-30
WO2002079198A1 (en) 2002-10-10
MA27003A1 (fr) 2004-12-20
IS8251A (is) 2006-01-23
HUP0303644A3 (en) 2008-06-30
EA006023B1 (ru) 2005-08-25
UY27237A1 (es) 2002-12-31
US6579879B2 (en) 2003-06-17
UA73236C2 (en) 2005-06-15
ES2274369T3 (es) 2007-05-16
IL156462A0 (en) 2004-01-04
NZ528406A (en) 2004-03-26
ATE348100T1 (de) 2007-01-15
MXPA03008850A (es) 2003-12-04
EP1373259B1 (en) 2004-12-29
CN1500087A (zh) 2004-05-26
SK11852003A3 (sk) 2004-07-07
KR20030088484A (ko) 2003-11-19
ATE286049T1 (de) 2005-01-15
PL365294A1 (en) 2004-12-27
BG108179A (en) 2004-09-30
EP1491540A1 (en) 2004-12-29
NO20034345L (no) 2003-09-29
DE60202452D1 (de) 2005-02-03
PT1373259E (pt) 2005-03-31
AU2002226634B2 (en) 2007-01-25
GEP20053675B (en) 2005-11-25
CA2442476A1 (en) 2002-10-10
HRP20030752A2 (en) 2005-06-30
DK1491540T3 (da) 2007-03-26
PA8541801A1 (es) 2002-10-28
US6849629B2 (en) 2005-02-01
PE20030007A1 (es) 2003-01-28
ATE352551T1 (de) 2007-02-15
DE60216823T2 (de) 2007-10-04
EP1491541B1 (en) 2007-01-24
IS2205B (is) 2007-02-15
TNSN02037A1 (fr) 2005-12-23
EP1491540B1 (en) 2006-12-13
SI1373259T1 (en) 2005-04-30
US20030162784A1 (en) 2003-08-28
AP2002002461A0 (en) 2002-06-30
DE60216823D1 (de) 2007-01-25
BR0208571A (pt) 2004-03-23
EE200300470A (et) 2004-02-16
IS8250A (is) 2006-01-23
EA200300673A1 (ru) 2003-12-25
OA12453A (en) 2006-05-24
US20020143017A1 (en) 2002-10-03
JP2004528319A (ja) 2004-09-16
ECSP034671A (es) 2003-08-29
EP1373259A1 (en) 2004-01-02
AR035798A1 (es) 2004-07-14
ES2231681T3 (es) 2005-05-16
CN1215067C (zh) 2005-08-17
IS6845A (is) 2003-06-16
DE60217930D1 (de) 2007-03-15
DE60202452T2 (de) 2006-02-09

Similar Documents

Publication Publication Date Title
JP2004528319A5 (enExample)
ZA200304671B (en) Pyridaxinone aldose reductase inhibitors.
DE60211348T2 (de) 2,4,5-trisubstituted thiazolyl derivative und deren antiinflammatorische wirkung
US6414149B1 (en) Sorbitol dehydrogenase inhibitors
AU2002363176B2 (en) Heteroaryl amines as glycogen synthase kinase 3Beta inhibitors (GSK3 inhibitors)
DE60215814T2 (de) Vinylphenyl-derivate als glk-aktivatoren
EP1442024B1 (en) AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3$g(b) INHIBITORS
CN112533904B (zh) 黑皮质素亚型-2受体(mc2r)拮抗剂及其用途
US8993598B2 (en) Pyrrole compounds
DE60316709T2 (de) Indole-3-carbonsaüreamide als glucokinase (gk) aktivatoren
EP2858983A1 (en) Tnf -alpha modulating benzimidazoles
CA2642922A1 (en) Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
JP2013505913A (ja) Ｃｒａｃ調節剤としてのインドール誘導体
BRPI0615111B1 (pt) Composto, composição farmacêutica, e, uso do composto
EP2527326B1 (en) Novel compounds having 4-pyridylalkylthio group as substituent
EP2515657A1 (en) Tyrosine kinase inhibitors
AU2014234906A1 (en) Cycloalkyl nitrile pyrazolo pyridones as Janus kinase inhibitors
CN101910172A (zh) N-杂环咪唑并[1，2-a]吡啶-2-甲酰胺衍生物、其制备方法及其治疗应用
MX2011010482A (es) Compustos y métodos para tratamiento antiviral.
JP2005232149A (ja) ４−ピリジルアルキルチオ基を置換基として有する新規化合物
ZA200307204B (en) Combinations of aldose reductase inhibitors and cyclooxygenase-2-inhibitors.
AU2012203026A1 (en) Novel heterocyclic compounds and uses thereof
HK1251815A1 (zh) 1-(杂)芳基磺酰基-(吡咯烷或哌啶)-2-甲酰胺衍生物及其作为trpa1拮抗剂的用途
HK1077507B (en) 2,4,5-trisubstituted thiazolyl derivatives ant their antiinflammatory activity
HK1062888B (en) Vinyl phenyl derivatives as glk activators

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8315 Request for restriction filed
8318 Patent restricted
8393 Patent changed during the limitation procedure (changed patent specification reprinted)
8339 Ceased/non-payment of the annual fee